Eloxx (ELOX) director Stephen Webster receives stock options for 13,587 shares

Rhea-AI Filing Summary

Eloxx Pharmaceuticals director Stephen W. Webster received a new stock option grant. On the reported date, he was awarded options to acquire 13,587 shares of Eloxx common stock at an exercise price of $11.00 per share. These options vest in 24 substantially equal monthly installments and will be fully vested on the second anniversary of the grant date, as long as he continues serving the company. Following this grant, Webster holds 13,587 stock options directly under this award, which are scheduled to expire on June 8, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Webster Stephen W

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	13,587	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 13,587 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 13,587 options Exercise price: $11.00 per share Underlying shares: 13,587 shares +3 more

6 metrics

Option grant size 13,587 options Stock Option (Right to Buy) granted to director

Exercise price $11.00 per share Conversion or exercise price of stock options

Underlying shares 13,587 shares Common Stock underlying the options

Total options after grant 13,587 options Total derivative securities following transaction

Vesting period 24 monthly installments Fully vested on second anniversary of grant date

Expiration date June 8, 2036 Option expiration date

Key Terms

Stock Option (Right to Buy), vesting, exercise price, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

vesting financial

"The stock option will vest in 24 substantially equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: 11.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-08T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Stephen W

(Last) (First) (Middle)

C/O ELOXX PHARMACEUTICALS, INC.

P.O. BOX 274

(Street)

ARLINGTON MASSACHUSETTS 02476

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Eloxx Pharmaceuticals, Inc. [ ELOX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11	06/08/2026		A		13,587		(1)	06/08/2036	Common Stock	13,587	$0	13,587	D

Explanation of Responses:

1. The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

	/s/ Sumit Aggarwal, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Eloxx Pharmaceuticals (ELOX) report for Stephen W. Webster?

Eloxx Pharmaceuticals reported that director Stephen W. Webster received a stock option grant for 13,587 shares. The options give him the right to buy common stock at a fixed exercise price, providing equity-based compensation tied to the company’s future performance.

How many Eloxx (ELOX) shares are covered by Stephen W. Webster’s new stock options?

The stock option grant covers 13,587 shares of Eloxx common stock. Each option represents the right to buy one share if exercised, aligning the director’s potential upside with shareholder value over the option’s life.

What is the exercise price and expiration date of Stephen W. Webster’s Eloxx (ELOX) options?

The options have an exercise price of $11.00 per share and expire on June 8, 2036. This means Webster can choose to exercise the options at that price any time after vesting and before the stated expiration date.

How do Stephen W. Webster’s Eloxx (ELOX) stock options vest over time?

The options vest in 24 substantially equal monthly installments, fully vesting on the second anniversary of the grant date. Vesting depends on Webster’s continuous service to Eloxx, encouraging ongoing engagement with the company’s long-term goals.

Is Stephen W. Webster’s Eloxx (ELOX) option grant an open-market purchase or a compensation award?

The filing classifies the transaction as a grant or award acquisition, not an open-market purchase. The options were issued at no cost as part of compensation, with value realized only if exercised above the $11.00 exercise price.